Boehringer Ingelheim International Gmbh

Joe Ju Gao

Bing-Shiou Yang

Jason Alan Mulder

Xingzhong Zeng

Keith R Fandrick

Peter Sieger

Jinhua Jeff Song

Zhi-Hui Lu

Fredrik Lars Nordstrom

Nitinchandra D Patel

Yongda Zhang

Wenjie Li

Manabu Nakatani

Jean-Nicolas Desrosiers

Gisela Bodenbach

Albert Josef Barta

Masashi Adachi

Michael Wiese

Kenji Egusa

Katrin Baer

Julia Regina Grimm

Roman Christian Messerschmid

Daniela Maria Schroeder

Keith R Fandrik

Jinhau J Song

The invention describes a process for reworking of a crystallization product comprising drying and homogenization. The crystallization product is crystalline [5-(methylsulfonyl)-2-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-yl]-3-azabicyclo[3.1.0]hex-3-yl}methanone. The product is dried in a tray dryer or in a pan dryer and subsequently homogenized.

Process of reworking a crystalline form of a glycine transport inhibitor

Disclosed are solid forms of an inhibitor of glycine transporter-1 (GlyT1). The invention also relates to methods of making these solid forms, pharmaceutical compositions comprising these solid forms, and their use for medical conditions responsive to treatment with an inhibitor of glycine transporter-1.

Solid forms of a GlyT1 inhibitor

The present invention relates to a process of making a compound of formula (XII) or (XIIA): wherein R,R, Rand X are as defined herein. 

Process for preparing carboxylic acids

The present invention relates to a process of making a compound of formula (I): Wherein, R, R, Rand X are as defined herein.

Process for preparing carboxamidine compounds

Disclosed are syntheses of 11&#x3b2;-HSD1 inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes, metabolic syndrome, obesity, glucose intolerance, insulin resistance, hyperglycemia, hypertension, hypertension-related cardiovascular disorders, hyperlipidemia, deleterious gluco-corticoid effects on neuronal function (e.g. cognitive impairment, dementia, and/or depression), elevated intra-ocular pressure, various forms of bone disease (e.g., osteoporosis), tuberculosis, leprosy (Hansen's disease), psoriasis, and impaired wound healing (e.g., in patients that exhibit impaired glucose tolerance and/or type 2 diabetes). 

Synthesis of inhibitors of 11&#x3b2;-hydroxysteroid dehydrogenase type 1

Growing community of inventors

Southbury, CT, United States of America

Joe Ju Gao